- Home
- VVPR vs CGTX Comparison
VVPR vs CGTX Comparison
Compare VVPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVPR
- CGTX
- Stock Information
- Founded
- VVPR 2014
- CGTX 2007
- Country
- VVPR United Kingdom
- CGTX United States
- Employees
- VVPR N/A
- CGTX N/A
- Industry
- VVPR Power Generation
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VVPR Utilities
- CGTX Health Care
- Exchange
- VVPR Nasdaq
- CGTX Nasdaq
- Market Cap
- VVPR 26.9M
- CGTX 23.1M
- IPO Year
- VVPR 2016
- CGTX 2021
- Fundamental
- Price
- VVPR $4.72
- CGTX $0.33
- Analyst Decision
- VVPR
- CGTX Strong Buy
- Analyst Count
- VVPR 0
- CGTX 5
- Target Price
- VVPR N/A
- CGTX $6.13
- AVG Volume (30 Days)
- VVPR 401.3K
- CGTX 942.4K
- Earning Date
- VVPR 01-01-0001
- CGTX 05-07-2025
- Dividend Yield
- VVPR N/A
- CGTX N/A
- EPS Growth
- VVPR N/A
- CGTX N/A
- EPS
- VVPR N/A
- CGTX N/A
- Revenue
- VVPR $79,000.00
- CGTX N/A
- Revenue This Year
- VVPR N/A
- CGTX N/A
- Revenue Next Year
- VVPR N/A
- CGTX N/A
- P/E Ratio
- VVPR N/A
- CGTX N/A
- Revenue Growth
- VVPR N/A
- CGTX N/A
- 52 Week Low
- VVPR $0.62
- CGTX $0.31
- 52 Week High
- VVPR $6.66
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- VVPR 73.57
- CGTX 39.84
- Support Level
- VVPR $2.35
- CGTX $0.30
- Resistance Level
- VVPR $5.00
- CGTX $0.34
- Average True Range (ATR)
- VVPR 0.43
- CGTX 0.03
- MACD
- VVPR 0.13
- CGTX -0.01
- Stochastic Oscillator
- VVPR 87.04
- CGTX 28.31
About VVPR VivoPower International PLC
Vivopower International PLC is a solar power company. It provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions, Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Electric Vehicles segment. Geographically its key revenue derives from the Netherlands.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.